Close Menu
The Cannabis Journal

    Subscribe to Updates

    Get the latest creative news from The Cannabis Journal

    What's Hot

    Trump’s Truth Social Post Sparks Buzz — Enthusiasts See New Signal

    September 29, 2025

    MMJ’s Cannabis Softgel Approach Offers a New Path in Huntington’s Disease — Scalable Alternative to Gene Therapy?

    September 26, 2025

    A New Alliance: Nvidia Invests in Intel Amidst Geopolitical Shifts

    September 23, 2025
    X (Twitter) Instagram
    The Cannabis JournalThe Cannabis Journal Monday, October 6
    Trending
    • Trump’s Truth Social Post Sparks Buzz — Enthusiasts See New Signal
    • MMJ’s Cannabis Softgel Approach Offers a New Path in Huntington’s Disease — Scalable Alternative to Gene Therapy?
    • A New Alliance: Nvidia Invests in Intel Amidst Geopolitical Shifts
    • Tilray and Sundial Growers Navigate Shifting Cannabis Landscape Amid Regulatory Optimism
    • The Value of REITs in a Dividend Portfolio: Spotlight on AGNC, Realty Income, and VICI
    • High Tide Poised for Strong Q3 Results After August Guidance — What to Watch
    • Klarna’s NYSE Debut: Europe’s BNPL Giant Eyes U.S. Expansion Amid Investor Buzz
    • Rescheduling Hope Ignites Buzz in Cannabis Industry — But Is the Optimism Warranted?
    The Cannabis JournalThe Cannabis Journal
    • Home
    • Cannabis News
    • Stocks
    • High Tide Inc.
    • About Us
    The Cannabis Journal
    Home»Companies»Trump Should Reschedule Cannabis On The Way To Fully Descheduling It, Roger Stone Says (Op-Ed)
    Companies

    Trump Should Reschedule Cannabis On The Way To Fully Descheduling It, Roger Stone Says (Op-Ed)

    The Cannabis JournalBy The Cannabis JournalAugust 28, 2025No Comments4 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    “If Trump makes the move to reschedule cannabis…he will be bringing Washington in line with the American people.”

    By Roger Stone

    In America today, no issue better demonstrates the yawning gulf between the will of the people and the paralysis of their government than cannabis policy. Overwhelming majorities of Americans believe cannabis should be legal in some form.

    Yet at the federal level, Washington has dithered, stumbled and flat-out failed—save for one notable exception.

    That exception is Donald J. Trump.

    The federal government’s dereliction has forced states to go it alone. Some have bravely enacted medical or adult-use cannabis laws, seeking to serve their citizens where Washington will not.

    But these state reforms collide head-on with federal policy, leaving consumers, patients and businesses in legal limbo. Imagine driving across state lines and discovering that what you bought legally at a dispensary—or even a 7-Eleven in some places—could earn you a felony in the next jurisdiction.

    That is not liberty. That is not fairness. And it is certainly not certainty.

    When Trump signed the 2018 Farm Bill, he unleashed the hemp economy—creating jobs, investment and innovation nationwide.

    Trump’s action didn’t just expand access to benign hemp products; it jump-started an entire industry. Hundreds of thousands of jobs and billions in investment now hang in the balance. Yet the industry remains shackled by uncertainty, because Washington refuses to reconcile federal law with reality.

    Now the question looms: what will Trump do next?

    The chattering class insists this is an “either/or” debate. Either Trump “reschedules” cannabis—moving it from Schedule I of the Controlled Substances Act (where heroin sits, absurdly) to a lower schedule—or he “deschedules” it entirely, removing cannabis from the Controlled Substances Act altogether and leaving states to decide.

    That framing is false. This is not about either/or. This is about progress. What must be done next.

    Rescheduling cannabis is not the end game, but it is the critical next step. The move would do more than signal a new direction—it would unlock immediate, measurable relief for patients, entrepreneurs and state programs.

    By moving cannabis to Schedule III, businesses would finally escape the crushing burden of IRS Code 280E, which currently denies them ordinary tax deductions. That single change would level the playing field, allowing dispensaries and cultivators to be taxed like normal businesses rather than penalized like criminals.

    Rescheduling would also open the door to banking. Today, cannabis companies are forced to operate largely in cash because banks fear federal money-laundering penalties. Schedule III would not solve every obstacle, but it would reduce the risk profile enough that many regional banks and credit unions could finally provide accounts, loans and payment processing. With that one action, Trump could dramatically reduce the public safety risks of cash-heavy businesses, increase tax compliance and unlock billions in private investment.

    Research, too, would flourish. Universities and pharmaceutical firms could study cannabis without jumping through near-impossible DEA hoops. Evidence would accumulate quickly, proving what millions already know: hemp is safe and useful, CBD is benign and medically valuable and THC deserves fair study as both medicine and a regulated product.

    Some parts of cannabis—like hemp as a building material or pulp source—should already be descheduled. CBD is another obvious candidate. THC, the psychoactive element, should remain under the microscope until research makes its case. But only through rescheduling can the studies happen, the myths be demolished, the banking bottleneck be relieved and the path to eventual descheduling be built on rock-solid evidence rather than political spin.

    The people are ready. The states are ready. The industry is desperate for certainty. And the only man who has shown the will to act is Donald Trump.

    If Trump makes the move to reschedule cannabis, he won’t just be adjusting federal drug policy—he will be correcting one of the greatest disconnects in American political life. He will be bringing Washington in line with the American people. And he will once again prove what his critics hate most: that Donald J. Trump gets things done.

    Roger Stone is a Republican political operative who has served as a senior campaign aide to three Republican presidents: Richard Nixon, Ronald Reagan and Donald Trump.

    Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleEuropean Parliament tightens rules on access for journalists and lobbyists – POLITICO
    Next Article MSOS ETF: The Cannabis Comeback Kid or a Wait-and-See Play?
    The Cannabis Journal
    • Website

    Related Posts

    Cannabis News

    Trump’s Truth Social Post Sparks Buzz — Enthusiasts See New Signal

    September 29, 2025
    Cannabis News

    MMJ’s Cannabis Softgel Approach Offers a New Path in Huntington’s Disease — Scalable Alternative to Gene Therapy?

    September 26, 2025
    Companies

    A New Alliance: Nvidia Invests in Intel Amidst Geopolitical Shifts

    September 23, 2025
    Add A Comment
    Leave A Reply Cancel Reply

    Latest

    Trump’s Truth Social Post Sparks Buzz — Enthusiasts See New Signal

    September 29, 20255 Views

    MMJ’s Cannabis Softgel Approach Offers a New Path in Huntington’s Disease — Scalable Alternative to Gene Therapy?

    September 26, 20252 Views

    A New Alliance: Nvidia Invests in Intel Amidst Geopolitical Shifts

    September 23, 20251 Views

    Tilray and Sundial Growers Navigate Shifting Cannabis Landscape Amid Regulatory Optimism

    September 17, 20255 Views
    Stay In Touch
    • Twitter
    • Instagram

    Subscribe to Updates

    Get the latest tech news from The Cannabis Journal.

    Most Popular

    High Tide Surges Ahead as Integrity and Scale Define Industry Leadership

    September 4, 20259 Views

    Tilray Stock: Stunning 5x Growth Potential Revealed

    August 26, 20258 Views

    German Retail Acquisition Pending for High Tide – New Cannabis Ventures

    August 21, 20258 Views
    Our Picks

    Trump’s Truth Social Post Sparks Buzz — Enthusiasts See New Signal

    September 29, 2025

    MMJ’s Cannabis Softgel Approach Offers a New Path in Huntington’s Disease — Scalable Alternative to Gene Therapy?

    September 26, 2025

    A New Alliance: Nvidia Invests in Intel Amidst Geopolitical Shifts

    September 23, 2025

    Subscribe to Updates

    Get the latest creative news from The Cannabis Journal

    Facebook X (Twitter) Instagram Pinterest
    • About Us
    • Contact Us
    • Privacy Policy
    • Terms & Conditions
    • Disclaimer
    © 2025 ThemeSphere. Designed by ThemeSphere.

    Type above and press Enter to search. Press Esc to cancel.

    Ad Blocker Enabled!
    Ad Blocker Enabled!
    To make it possible to run this website, we would love to show you some ads! Please <3 Thanks - The Cannabis Journal